See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Liberation Day
Donald Trump
Natural Disasters
Trade War
Nintendo
Social Media
European Union
Stock Markets
Trade
Taxes
Baseball
Published • loading... • Updated

Experimental women's cancer drug boosts survival rates in notable study

Summary by Ground News
A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve overall survival and progression of the disease when matched with a chemotherapy drug called nab-paclitaxel.

2 Articles

All
Left
Center
1
Right
1
News MedicalNews Medical
Center

Unraveling resistance to CDK4/6 inhibitors in ovarian cancer

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies.

·United States
Read Full Article
Fox NewsFox News
Right

Experimental women's cancer drug boosts survival rates in notable study

Researchers discuss encouraging findings on a new drug tested in a phase 3 trial, which showed significant improvement in patients with treatment-resistant ovarian cancer.

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Fox News broke the news in New York, United States on Tuesday, April 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Cancer

Cancer

Research

Research

Health

Health

Science

Science

Medical

Medical

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal